Jim Klein is interim Chief Financial Officer with responsibility for finance, treasury, and general administration. Mr. Klein has over 30 years of senior financial leadership experience in the pharmaceutical, biotech, and medical device industries. He has raised over $400 million as a Chief Financial Officer of various life science companies, including two successful initial public offerings.
Mr. Klein specializes in managing growth to entrepreneurial companies, providing executive financial management, long-range strategic planning, financial reporting, cash and treasury management, and operational management. He is well-versed at working with boards of directors, including compensation and audit committees.
Mr. Klein graduated from the University of Mississippi with a degree in accounting and is a Certified Public Accountant. Mr. Klein has also attended executive management programs at the London Business School; the Fuqua School of Business at Duke University; and the Kenan-Flagler Business School at The University of North Carolina.